Full-Time

Forward Deployed Engineer Manager

Updated on 8/23/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid work in Hyderabad is required.

Bachelor's, Master's

Category
Software Engineering (1)
Required Skills
LLM
Kubernetes
MLOps
Data Lake
Redshift
Git
BigQuery
Apache Spark
Machine Learning
Data Engineering
Infrastructure as Code (IaC)
Docker
RAG
Microservices
AWS
Cryptography
DevOps
Databricks
Serverless
Google Cloud Platform

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Hands-on experience with AWS and Google Cloud Platform cloud services, including compute, storage, networking, security, data platforms, artificial intelligence and machine learning services, and observability capabilities.
  • Strong experience delivering enterprise-grade artificial intelligence and machine learning solutions using modern cloud architecture patterns within large, global technology organizations.
  • Deep understanding of microservices, containers, Kubernetes, serverless, event-driven architecture, application programming interface-based integration, data lake and lakehouse architectures, and distributed processing.
  • Strong understanding of the artificial intelligence and machine learning lifecycle, including data preparation, feature engineering, model training, model evaluation, deployment, monitoring, retraining, and governance.
  • Experience designing Generative AI solutions using large language models, Retrieval-Augmented Generation, vector search, semantic search, enterprise knowledge retrieval, and knowledge graph-based architectures.
  • Hands-on knowledge of Agentic AI architecture, including agent frameworks, multi-agent orchestration, autonomous workflow design, tool use, planning patterns, guardrails, and enterprise integration.
  • Strong understanding of prompt engineering, prompt lifecycle management, prompt evaluation, reusable prompt patterns, and operational controls for Generative AI applications.
  • Knowledge of DevOps practices and tools, including continuous integration and continuous delivery pipelines, Git-based workflows, automated deployments, infrastructure as code, containerization, and environment management.
  • Experience with MLOps concepts and tooling for automated model deployment, model registries, experiment tracking, model monitoring, and drift detection.
  • Ability to design secure, compliant, and resilient cloud solutions with identity and access management, encryption, network controls, logging, and auditability.
  • Knowledge of AI governance practices, including responsible AI implementation, AI risk assessment, model explainability and transparency, human-in-the-loop controls, validation, monitoring, and regulatory readiness.
  • Demonstrated ability to work in forward-deployed or embedded engineering models, including rapid discovery, solution shaping, prototyping, user validation, production delivery, and adoption support.
  • Bachelor’s or Master’s degree in Computer Science, Engineering, Data Science, Information Technology, or a related discipline.
  • At least 10 years of overall technology experience, including significant experience in hands-on engineering, solution architecture, cloud platforms, data engineering, artificial intelligence and machine learning, Generative AI, or enterprise solution delivery.
  • At least 10 years of experience designing and implementing cloud-native solutions on AWS, Google Cloud Platform, or multi-cloud environments.
  • Prior experience leading hands-on solution delivery, architecture discussions, design reviews, technical roadmaps, minimum viable product development, and cross-functional delivery teams.
  • Ability to operate effectively in ambiguous business environments and convert user needs into scalable technical solutions.
  • Strong stakeholder management and communication skills, including the ability to explain complex architecture decisions to technical and business audiences.
Responsibilities
  • Partner with business, product, clinical, scientific, data science, engineering, and technology stakeholders to identify high-impact use cases and translate them into deployable artificial intelligence, machine learning, and Generative AI solutions.
  • Rapidly prototype, validate, iterate, and deploy AI-enabled products, workflows, and platform capabilities with users and delivery teams.
  • Design scalable and reusable cloud architecture patterns across AWS and Google Cloud Platform, including serverless, containerized, microservices-based, event-driven, data lake, lakehouse, and hybrid cloud patterns.
  • Design and implement Generative AI solutions using large language models, Retrieval-Augmented Generation, semantic search, knowledge graphs, and enterprise knowledge integration.
  • Architect Agentic AI solutions, including autonomous AI workflows, multi-agent orchestration, agentic frameworks, tool integration, guardrails, and human-in-the-loop controls.
  • Embed with global product, data science, engineering, security, infrastructure, architecture, and business teams to convert ambiguous business requirements into secure, scalable, production-ready technical solutions.
  • Evaluate and recommend cloud-native AI and machine learning services, data platforms, compute options, integration patterns, and automation frameworks aligned with enterprise architecture standards.
  • Establish prompt engineering, prompt management, evaluation, versioning, reuse, and lifecycle practices for scalable Generative AI delivery.
  • Ensure architecture decisions meet performance, reliability, scalability, security, privacy, compliance, cost optimization, and operational resilience requirements in a regulated healthcare environment.
  • Provide hands-on technical leadership to engineering teams through implementation support, reference architectures, design reviews, code-level guidance, and technical standards.
  • Drive adoption of DevOps and MLOps practices, including continuous integration and continuous delivery, infrastructure as code, automated testing, model deployment automation, monitoring, alerting, and release governance.
  • Collaborate with governance, privacy, cybersecurity, quality, and compliance stakeholders to align AI and machine learning solutions with enterprise standards and regulatory expectations.
  • Implement responsible AI and AI governance practices, including AI risk assessments, model explainability, transparency, validation, monitoring, and regulatory readiness.
  • Support solution roadmaps, technology evaluations, proofs of concept, minimum viable product delivery, user feedback cycles, production rollout, and modernization initiatives.
  • Act as a technical partner for stakeholders by bridging strategy, architecture, engineering execution, adoption, and measurable business outcomes.
Desired Qualifications
  • Experience in clinical development, pharmaceutical research and development, healthcare, life sciences, medical technology, or other regulated domains.
  • Understanding of clinical development workflows, clinical trial data, regulated data platforms, privacy requirements, GxP considerations, and compliance-driven technology delivery.
  • Experience with AWS services such as SageMaker, Lambda, Elastic Container Service, Elastic Kubernetes Service, S3, Glue, Redshift, Identity and Access Management, CloudWatch, and related data or AI and machine learning services.
  • Experience with Google Cloud Platform services such as Vertex AI, BigQuery, Cloud Storage, Google Kubernetes Engine, Cloud Run, Cloud Functions, Pub/Sub, Identity and Access Management, and Cloud Monitoring.
  • Exposure to data engineering platforms, lakehouse architectures, Databricks, Spark, orchestration tools, and modern analytics platforms.
  • Cloud or architecture certifications such as AWS Solutions Architect, AWS Machine Learning Specialty, Google Professional Cloud Architect, or Google Professional Machine Learning Engineer.
  • Prior experience working in an innovative pharmaceutical company in a research and development domain.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.